DPX-Based Vaccines to Fight Against Infectious Diseases
DPX-RSV is a small B cell epitope peptide vaccine designed specifically to address the unmet medical needs in respiratory syncytial virus (RSV).
View DPX-RSVWe Focus on Unmet Medical Needs
CPA = intermittent low dose CPA
DPX-Survivac: Our Lead Candidate To Tackle Hard-To-Treat Cancers
DPX-Survivac is a T cell activating immunotherapy that combines the power of our propriety DPX Platform with cancer antigen survivin. DPX-Survivac is the lead clinical candidate in IMV’s new class of immunotherapies that generates targeted T cells in vivo. By activating survivin-specific killer T cells, DPX-Survivac promotes the destruction of cancer cells and disrupt the fundamental processes of cancer cell production and survival.
View DPX-Survivac
In response to the current COVID-19 outbreak, IMV Inc. is developing a vaccine against the SARS-CoV2 based on its unique DPX platform that activates B and T cells responses, even in older or immunocompromised adults. Fully synthetic, DPX-COVID-19 offers the potential for accelerated development and rapid, large-scale production. The first patient should receive DPX-COVID-19 during the summer of 2020.
View DPX-COVID-19